**To:** [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @health.fgov.be[ [redacted] @health.fgov.be]; [redacted] @commissariat.fed.be[ [redacted] @commissariat.fed.be]; [redacted] @fagg-afmps.be[ [redacted] @fagg-afmps.be]; [redacted] @dgtresor.gouv.fr[ [redacted] @dgtresor.gouv.fr]; [redacted] @igf.finances.gouv.fr[ [redacted] @igf.finances.gouv.fr]; [redacted] @bmg.bund.de[ [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de[ [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de[ [redacted] @bmg.bund.de]; [redacted] @bmg.bund.de[ [redacted] @bmg.bund.de]; [redacted] @hse.ie[ [redacted] @hse.ie]; [redacted] @health.gov.ie[ [redacted] @health.gov.ie]; [redacted] @sanita.it[ [redacted] @sanita.it]; [redacted] @covid19.difesa.it[ [redacted] @covid19.difesa.it]; [redacted] @covid19.difesa.it[ [redacted] @covid19.difesa.it]; [redacted] @ms.etat.lu[ [redacted] @ms.etat.lu]; [redacted] @ms.etat.lu[ [redacted] @ms.etat.lu]; [redacted] @minvws.nl[ [redacted] @minvws.nl]; [redacted] @minbuza.nl[ [redacted] @minbuza.nl]; [redacted] @infarmed.pt[ [redacted] @infarmed.pt]; [redacted] @infarmed.pt[ [redacted] @infarmed.pt]; [redacted] @aemps.es[ [redacted] @aemps.es]

**Cc:** [redacted] @PFIZER.COM[ [redacted] @PFIZER.COM]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ext.ec.europa.eu[ [redacted] @ext.ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @mfa.no[ [redacted] @mfa.no]; [redacted] @gov.se[ [redacted] @gov.se]; [redacted] @ec.europa.eu[ [redacted] @ec.europa.eu]; [redacted] @Pfizer.com[ [redacted] @Pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @pfizer.com[ [redacted] @pfizer.com]; [redacted] @Pfizer.com[ [redacted] @Pfizer.com]

**From:** [redacted] @aemps.es
**Sent:** Mon 10/11/2021 4:55:21 PM
**Subject:** RE: IMPORTANT UPDATE_ [CONFIDENTIAL] BioNTech-Pfizer - Pausing ofDoses - Q4 2021 - Breakdown donations to COVAX vs. bilateral donations/resell
**Received:** Mon 10/11/2021 4:55:28 PM
Copia de EC Q4 Donations_8 OCT 2021 (003).xlsx

Dear [redacted]

We have signed today the mandate to FR to donate to COVAX. We would like to maintain the same earmarking we have for other vaccines that is well known by COVAX. Please, fin the table amended accordingly.

Best regards,

[redacted]
Departamento de Medicamentos de Uso Humano/*Department of Medicines for Human Use*
**Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)**
Calle Campezo 1 • Edificio 8 • E-28022 Madrid • España/Spain

CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addressee. If you are not the addressee, we ask you to notify to the sender, do not pass its content and delete the original.

[redacted]

Pagina's zijn verwijderd 1541801

2 - 6

Dubbel